Olema Pharmaceuticals (OLMA) 10-Q 7 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 03, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Entity File Number	001-39712
Entity Registrant Name	OLEMA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	30-0409740
Entity Address, Address Line One	780 Brannan Street
Entity Address, City or Town	San Francisco
Entity Address, Country	CA
Entity Address, Postal Zip Code	94103
City Area Code	650
Local Phone Number	243-5555
Title of 12(b) Security	Common Stock
Trading Symbol	OLMA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		54,769,800
Entity Central Index Key	0001750284
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 117,407	$ 23,702
Marketable securities	159,494	180,719
Prepaid expenses and other current assets	5,107	4,478
Total current assets	282,008	208,899
Property and equipment, net	1,056	1,480
Operating lease right-of-use assets	2,558	2,495
Other assets and long-term deposits	7,177	2,771
Total assets	292,799	215,645
Current liabilities:
Accounts payable	2,207	374
Operating lease liabilities, current	924	1,015
Accrued and other current liabilities	12,835	15,160
Total current liabilities	15,966	16,549
Operating lease liabilities, net of current portion	1,699	1,550
Total liabilities	17,665	18,099
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued and outstanding as of September 30, 2023 and December 31, 2022.
Common stock, $0.0001 par value; 490,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 54,749,472 and 40,601,648 shares issued as of September 30, 2023 and December 31, 2022, respectively; 54,601,516 and 40,287,097 shares outstanding as of September 30, 2023 and December 31, 2022, respectively.	4	3
Additional paid-in capital	554,231	408,333
Accumulated other comprehensive loss	(241)	(1,813)
Accumulated deficit	(278,860)	(208,977)
Total stockholders' equity	275,134	197,546
Total liabilities and stockholders' equity	$ 292,799	$ 215,645

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Condensed Consolidated Balance Sheets (Unaudited)
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	490,000,000	490,000,000
Common stock, issued (in shares)	54,749,472	40,601,648
Common stock, outstanding (in shares)	54,601,516	40,287,097

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 19,453	$ 17,627	$ 60,268	$ 60,690
General and administrative	3,889	5,595	14,277	19,079
Total operating expenses	23,342	23,222	74,545	79,769
Loss from operations	(23,342)	(23,222)	(74,545)	(79,769)
Other income (expense):
Interest income	1,919	622	4,774	1,255
Other expense	(79)	(120)	(112)	(94)
Total other income	1,840	502	4,662	1,161
Net loss	$ (21,502)	$ (22,720)	$ (69,883)	$ (78,608)
Net loss per share, basic (in dollars per share)	$ (0.48)	$ (0.57)	$ (1.66)	$ (1.97)
Net loss per share, diluted (in dollars per share)	$ (0.48)	$ (0.57)	$ (1.66)	$ (1.97)
Weighted average shares used to compute net loss per share, basic (in shares)	44,977,161	40,036,201	41,999,978	39,930,418
Weighted average shares used to compute net loss per share, diluted (in shares)	44,977,161	40,036,201	41,999,978	39,930,418

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
Net loss	$ (21,502)	$ (22,720)	$ (69,883)	$ (78,608)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	277	(276)	1,572	(2,525)
Total comprehensive loss	$ (21,225)	$ (22,996)	$ (68,311)	$ (81,133)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Gain	Accumulated Deficit	Total
Balances, at Beginning of period at Dec. 31, 2021	$ 3	$ 388,904	$ (149)	$ (104,190)	$ 284,568
Balances, at Beginning of period (in shares) at Dec. 31, 2021	39,797,263
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised stock options		93			93
Vesting of early exercised stock options (in shares)	20,969
Vesting of restricted stock awards (in shares)	147,955
Exercise of stock options		146			146
Exercise of stock options (in shares)	87,490
Issuance of shares under employee stock purchase plan		57			57
Issuance of shares under employee stock purchase plan (in shares)	30,891
Stock-based compensation expense		13,704			13,704
Employee stock purchase plan expense		264			264
Net unrealized gain (loss) on marketable securities			(2,525)		(2,525)
Net loss				(78,608)	(78,608)
Balances, at End of period at Sep. 30, 2022	$ 3	403,168	(2,674)	(182,798)	217,699
Balances, at End of period (in shares) at Sep. 30, 2022	40,084,568
Balances, at Beginning of period at Jun. 30, 2022	$ 3	398,756	(2,398)	(160,078)	236,283
Balances, at Beginning of period (in shares) at Jun. 30, 2022	39,974,459
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised stock options		31			31
Vesting of early exercised stock options (in shares)	6,990
Vesting of restricted stock awards (in shares)	49,318
Exercise of stock options		106			106
Exercise of stock options (in shares)	53,801
Stock-based compensation expense		4,207			4,207
Employee stock purchase plan expense		68			68
Net unrealized gain (loss) on marketable securities			(276)		(276)
Net loss				(22,720)	(22,720)
Balances, at End of period at Sep. 30, 2022	$ 3	403,168	(2,674)	(182,798)	217,699
Balances, at End of period (in shares) at Sep. 30, 2022	40,084,568
Balances, at Beginning of period at Dec. 31, 2022	$ 3	408,333	(1,813)	(208,977)	197,546
Balances, at Beginning of period (in shares) at Dec. 31, 2022	40,287,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised stock options		80			$ 80
Vesting of early exercised stock options (in shares)	18,640
Vesting of restricted stock awards (in shares)	147,955				147,955
Exercise of stock options		2,443			$ 2,443
Exercise of stock options (in shares)	665,902				705,347
Issuance of shares under equity private placement, net of issuance costs of $240	$ 1	129,759			$ 129,760
Issuance of shares under equity private placement, net of issuance costs of $240 (in shares)	13,211,381
Issuance of shares under employee stock purchase plan		711			711
Issuance of shares under employee stock purchase plan (in shares)	270,541
Stock-based compensation expense		12,574			12,574
Employee stock purchase plan expense		331			331
Net unrealized gain (loss) on marketable securities			1,572		1,572
Net loss				(69,883)	(69,883)
Balances, at End of period at Sep. 30, 2023	$ 4	554,231	(241)	(278,860)	275,134
Balances, at End of period (in shares) at Sep. 30, 2023	54,601,516
Balances, at Beginning of period at Jun. 30, 2023	$ 3	419,456	(518)	(257,358)	161,583
Balances, at Beginning of period (in shares) at Jun. 30, 2023	41,122,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised stock options		20			20
Vesting of early exercised stock options (in shares)	4,660
Vesting of restricted stock awards (in shares)	49,318
Exercise of stock options		891			891
Exercise of stock options (in shares)	213,675
Issuance of shares under equity private placement, net of issuance costs of $240	$ 1	129,759			129,760
Issuance of shares under equity private placement, net of issuance costs of $240 (in shares)	13,211,381
Stock-based compensation expense		4,019			4,019
Employee stock purchase plan expense		86			86
Net unrealized gain (loss) on marketable securities			277		277
Net loss				(21,502)	(21,502)
Balances, at End of period at Sep. 30, 2023	$ 4	$ 554,231	$ (241)	$ (278,860)	$ 275,134
Balances, at End of period (in shares) at Sep. 30, 2023	54,601,516

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
Stock issuance costs	$ 240	$ 240

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (69,883)	$ (78,608)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	289	260
Loss on sale of equipment	111
Non-cash lease expense	973	975
Non-cash interest income on marketable securities	(3,253)	(216)
Stock-based compensation expense, including employee stock purchase plan expense	12,905	13,968
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	293	61
Other assets and long-term deposits	(5,328)	(1,114)
Accounts payable	1,833	(9)
Accrued and other current liabilities	(2,223)	3,281
Operating lease liabilities	(968)	(952)
Net cash used in operating activities	(65,251)	(62,354)
Cash flows from investing activities:
Purchase of equipment		(190)
Maturities of marketable securities	196,760	244,500
Purchases of marketable securities	(170,710)	(169,167)
Disposal of fixed assets	14
Net cash provided by investing activities	26,064	75,143
Cash flows from financing activities:
Proceeds from exercise of stock options	2,421	146
Proceeds from issuance of common stock under employee stock purchase plan	711	57
Proceeds from equity private placement, net of issuance costs of $240	129,760
Net cash provided by financing activities	132,892	203
Net increase in cash and cash equivalents	93,705	12,992
Cash and cash equivalents at beginning of period	23,702	13,812
Cash and cash equivalents at end of period	$ 117,407	$ 26,804

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Condensed Consolidated Statements of Cash Flows (unaudited)
Net of issuance costs	$ 240

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Nature of the Business and Basis of Presentation
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Olema Pharmaceuticals, Inc. (“Olema” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation targeted therapies for women’s cancers. The Company is initially focused on developing therapies for the treatment of breast cancer. The Company’s wholly-owned, lead product candidate, palazestrant (OP-1250), is a novel oral therapy with combined activity as both a complete estrogen receptor (“ER”) antagonist (“CERAN”) and a selective ER degrader (“SERD”). We expect to enroll the first patient in our proposed Phase 3 monotherapy clinical trial for the treatment of advanced or metastatic breast cancer (OPERA-01) in the fourth quarter of 2023. Palazestrant is also currently being evaluated in Phase 1b/2 clinical studies in combination with palbociclib, ribociclib, and alpelisib, in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (“ER+”), human epidermal growth factor receptor 2 negative (“HER2-”) breast cancer. Furthermore, we announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers. The Company is located in San Francisco, California and was incorporated in Delaware on August 7, 2006, under the legal name of CombiThera, Inc. and on March 25, 2009, was renamed Olema Pharmaceuticals, Inc. The Company’s principal operations are based in San Francisco, California, and it has operations in Cambridge, Massachusetts. Olema Oncology Australia Pty Ltd was incorporated on January 6, 2021, and is a wholly-owned subsidiary of the Company (collectively with Olema Pharmaceuticals, Inc., referred to as “Olema” or the “Company” herein). It operates in one business segment and therefore has only one reportable segment. The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of geopolitical and macroeconomic events discussed in further detail below, the ability to secure additional capital to fund operations and commercial success of its product candidates. Palazestrant and any future product candidates the Company may develop will require extensive nonclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Private Placement On September 5, 2023, the Company entered into a securities purchase agreement with institutional and accredited investors for the private placement of 13,211,381 shares of the Company’s common stock (the “Private Placement”) at a price of $9.84 per share, resulting in gross proceeds of approximately $130.0 million. After deducting offering expenses related to the Private Placement of approximately $0.2 million, the net proceeds to the Company from the Private Placement were approximately $129.8 million. The Private Placement closed on September 12, 2023 . Liquidity The Company had $276.9 million of cash, cash equivalents and marketable securities at September 30, 2023, in addition to an available balance of $25.0 million under the Loan and Security Agreement (the “Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”). Management believes that the Company’s cash, cash equivalents, marketable securities, and the amounts available under the Loan Agreement will be sufficient to fund the Company’s current operating plan into 2027. Impact of Geopolitical and Macroeconomic Events Global economic and business activities continue to face widespread geopolitical and macroeconomic uncertainties, including labor shortages, inflation rates and the responses by central banking authorities to control such inflation, monetary supply shifts and related financial market risks and instability, risk of a U.S. government shutdown, recession risks, as well as potential disruptions from the Russia-Ukraine conflict and armed conflict between Israel and groups based in surrounding regions, all of which have resulted in volatility in the U.S. and global financial markets and which have led to, and may continue to lead to, additional disruptions to trade, commerce, pricing stability, credit availability and supply chain continuity globally. The extent of the impact of these factors on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted. Any continued or renewed disruption resulting from these factors could negatively impact the Company’s business. The Company continues to monitor the impact of these geopolitical and macroeconomic factors on its results of operations, financial condition and cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting, and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements include the accounts of Olema Pharmaceuticals, Inc. and its wholly-owned subsidiary, Olema Oncology Australia Pty Ltd. All intercompany balances and transactions have been eliminated upon consolidation. Unaudited Interim Financial Information The interim condensed consolidated balance sheet as of September 30, 2023, and the statements of operations and comprehensive loss, and stockholders’ equity for the three and nine months ended September 30, 2023 and 2022, and the statements of cash flows for the nine months ended September 30, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial statements included in this report. The financial data and the other information disclosed in these notes to the condensed consolidated financial statements related to the three- and nine-month periods are also unaudited. The results of operations presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results to be expected for the year ending December 31, 2023, or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K as filed with the SEC on March 9, 2023 (the “Annual Report”). Use of Estimates The accompanying condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Significant areas that require management’s estimates include accruals of research and development expenses, including accrual of research contract costs, stock-based compensation assumptions, including the fair value of common stock. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or fewer at the date of purchase. Cash deposits are all in reputable financial institutions in the United States as of September 30, 2023, and December 31, 2022. Cash and cash equivalents consisted of cash on deposit with U.S. banks, including the Company’s bank account for its Australia subsidiary, denominated in U.S. dollars and Australian dollars and investments in interest bearing money market funds. Marketable Securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each balance sheet date. Unrealized gains and losses are excluded from net loss and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest earned on marketable securities is included in interest income. The Company periodically assesses its available-for-sale marketable securities for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through other expense. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through other expense, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive loss. The Company has not recorded any impairments for its marketable securities. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company invests in a variety of financial instruments and, by its policy, limits these financial instruments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks and corporations, subject to certain concentration limits. The Company’s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit with individual banking institutions may at times exceed the limits insured by the Federal Deposit Insurance Corporation (“FDIC”); however, the Company has not experienced any losses on such deposits. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships, dependence on key individuals or sole-source suppliers, and geopolitical and macroeconomic factors. The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company were denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. Leases The Company adopted Accounting Standard Update (“ASU”) 2016-12, Leases At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease, the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or finance lease; and (iv) recognizes lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses the incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. Most leases include options to renew and, or terminate the lease, which can impact the lease term. The exercise of these options is at the Company’s discretion. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. For any lease modification, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate that reflects the modified lease term, and adjusts the related ROU asset under the lease modification guidance under Topic 842. The Company has operating leases for its research and development and office facilities. Fixed lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our condensed consolidated statements of operations and comprehensive loss. The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less. Additional information and disclosures required by Topic 842 are contained in Note 11 “Lease” in the Annual Report. Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates. These costs are recorded within research and development expenses in the condensed consolidated statements of operations and include personnel expenses, stock-based compensation expenses, allocated general and administrative expenses, and external costs including fees paid to consultants and contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), in connection with nonclinical studies and clinical trials, and other related clinical trial fees, such as for investigator fees, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses and other current assets. Such amounts are recognized as an expense as the goods are delivered or the related services are performed. Costs incurred in obtaining technology licenses that do not meet the definition of a business are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future uses. Reimbursements of certain costs associated with research activities performed under the agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) are recorded as a reduction of research and development expenses and as a receivable due from Novartis, which is recorded under prepaid expenses and other current assets in the accompanying condensed consolidated financial statements, as described in Note 10, Commitments and Contingencies – Clinical Collaboration and Supply Agreement. Research Contract Costs and Accruals The Company has from time to time entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the projects, studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Net Loss Per Common Share Basic net loss per common share is computed by dividing the net loss per common share by the weighted average number of common shares outstanding for the period without consideration of common stock equivalents. Diluted net loss per common share is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities, and by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, including unvested early exercised options, unvested restricted stock awards, unvested performance-based restricted stock unit awards and contingently issuable common stock related to the 2020 Employee Stock Purchase Plan (the “ESPP”) are considered potential dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Recent Accounting Pronouncements There were no new accounting pronouncements that were relevant to the Company as of and for the nine months ended September 30, 2023. ​

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement
Fair Value Measurement	3. Fair Value Measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements ● Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. ● Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 (in thousands) Level 1 ​ Level 2 ​ Level 3 ​ Total Financial Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash ​ $ 2,712 ​ $ — ​ $ — ​ $ 2,712 Money market funds ​ ​ 115,029 ​ ​ — ​ ​ — ​ ​ 115,029 Commercial paper ​ — ​ ​ 87,639 ​ ​ — ​ ​ 87,639 Corporate bonds ​ ​ — ​ ​ 3,626 ​ ​ — ​ ​ 3,626 U.S. government treasury bills ​ ​ 37,395 ​ ​ — ​ ​ — ​ ​ 37,395 Government-sponsored enterprise securities ​ — ​ ​ 30,834 ​ ​ — ​ ​ 30,834 Total ​ $ 155,136 ​ $ 122,099 ​ $ — ​ $ 277,235 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Estimated (in thousands) Cost ​ Gains ​ Losses ​ Fair Value Financial Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 117,741 ​ $ — ​ $ — ​ $ 117,741 Short-term marketable securities (<12 months to maturity) ​ ​ 156,108 ​ ​ 9 ​ ​ (249) ​ ​ 155,868 Long-term marketable securities (>12 months to maturity) ​ ​ 3,627 ​ ​ — ​ ​ (1) ​ ​ 3,626 Total ​ $ 277,476 ​ $ 9 ​ $ (250) ​ $ 277,235 ​ The Company considers its marketable securities with maturities beyond one year as current assets, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. The Company periodically reviews its available-for-sale marketable securities for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. There were seven marketable securities that have been in a consecutive loss position for more than 12 months as of September 30, 2023. These marketable securities had $0.1 million unrealized losses with a fair value of $19.4 million as of September 30, 2023. The Company does not believe that the total unrealized losses of $0.3 million as of September 30, 2023 are credit-related but are rather a reflection of current market yields and/or current marketplace bid/ask spreads. During the three and nine months ended September 30, 2023, the Company did not recognize any other-than-temporary impairment loss. As of September 30, 2023, there was no allowance for losses on available-for-sale debt securities attributable to credit risk. As of September 30, 2023, all of the Company’s cash and cash equivalents consisted of cash on deposit with U.S. banks denominated in U. S. dollars and Australian dollars.

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2023
Property and Equipment, net
Property and Equipment, net	4. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Lab equipment $ 1,695 $ 2,002 Computer equipment ​ ​ 59 ​ ​ 59 Property and equipment, gross ​ ​ 1,754 ​ ​ 2,061 Less: Accumulated depreciation (698) ​ ​ (581) Property and equipment, net $ 1,056 ​ $ 1,480 ​

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Reimbursable research and development costs from a collaboration partner ​ $ 2,467 ​ $ 1,387 Prepaid clinical development costs ​ 1,003 ​ 506 Prepaid insurance ​ ​ 384 ​ ​ 1,738 Interest receivable ​ ​ 419 ​ ​ 319 Research and development tax incentive credit receivable ​ ​ 321 ​ ​ — Prepaid subscriptions and licenses ​ ​ 239 ​ ​ 399 Other 274 ​ ​ 129 Total $ 5,107 ​ $ 4,478 ​

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2023
Accrued and Other Current Liabilities
Accrued and Other Current Liabilities	6. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Accrued research and development related costs ​ $ 8,370 ​ $ 9,105 Accrued employee bonuses ​ ​ 2,849 ​ ​ 4,518 Accrued professional fees ​ ​ 1,143 ​ ​ 1,091 Accrued payroll related costs ​ ​ 416 ​ ​ 296 Accrued taxes ​ ​ 57 ​ ​ 68 Early exercise of unvested stock options ​ ​ — ​ ​ 82 Total $ 12,835 ​ $ 15,160 ​

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation
Stock-Based Compensation	7. Stock-Based Compensation ​ In 2014, the Company’s Board of Directors (the “Board”) and stockholders approved and adopted the Company’s 2014 Stock Plan (the “2014 Plan”). The 2014 Plan permitted the grant of options and restricted stock awards (including restricted stock purchase rights and restricted stock bonus awards). The 2014 Plan was terminated on the date the Company’s 2020 Equity Incentive Plan (the “2020 Plan”), which is described below, became effective, and since that date, no additional awards have been or will be made pursuant to the 2014 Plan. However, any outstanding awards granted under the 2014 Plan will remain outstanding, subject to the terms of the 2014 Plan award agreements, until such outstanding options are exercised or until any awards terminate or expire by their terms. In 2020, the Board and the Company’s stockholders approved and adopted the 2020 Plan. The 2020 Plan permits the grant of options, restricted stock awards, stock appreciation rights, restricted stock unit awards, performance awards, and other awards. The maximum number of shares of common stock that initially issuable under the 2020 Plan was a number not to exceed 6,494,510 shares of the Company’s common stock, which is the sum of (i) 2,152,080 new shares, plus (ii) an additional number of shares not to exceed 4,342,430 shares, consisting of any shares of the Company’s common stock subject to outstanding stock options or other stock awards granted under the 2014 Plan that, on or after the date on which the 2020 Plan became effective, terminated or expired prior to exercise or settlement; were not issued because the award was settled in cash; were forfeited because of the failure to vest; or were reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of the Company’s common stock reserved for issuance under the 2020 Plan automatically increases on January 1 of each year for a period of ten years, beginning on January 1, 2021 and continuing through January 1, 2030, in an amount equal to the lesser of (1) 5% of the total number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding year, or (2) a lesser number of shares determined by the Company’s Board of Directors no later than December 31 of the immediately preceding year. In 2022, the Board approved and adopted the Company’s 2022 Inducement Plan (the “2022 Inducement Plan”). Under the 2022 Inducement Plan, initially 2,000,000 shares of common stock were reserved for issuance. The 2022 Inducement Plan permits the grant of options, restricted stock awards, stock appreciation rights, restricted stock unit awards, performance awards, and other awards. The exercise price for each option and stock appreciation right shall be established at the discretion of the Board, provided that the exercise price of a stock option will not be less than 100% of the fair market value of the Company’s common stock on the date of grant. Specific vesting for stock options and stock appreciation rights is service related and determined in each award agreement, where stock options and stock appreciation rights are fully vested at the grant date or follow a graded vesting schedule. Stock options and stock appreciation rights granted under the plans generally expire ten years after the date of grant. Stock Option Valuation The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies in addition to its own historical volatility. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to nonemployees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is 0% since the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The assumptions that the Company used to determine the estimated grant-date fair value of stock options granted to employees and directors under the 2020 Plan and the 2022 Inducement Plan were as follows, presented as a weighted average: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2023 ​ 2022 Risk-free interest rate ​ 3.56% ​ 1.89% Expected term (in years) ​ ​ 6.03 ​ ​ 6.03 Expected volatility ​ ​ 86.71% ​ ​ 79.55% Expected dividend yield — ​ ​ — ​ Stock Option Activity The following table summarizes the stock option activity under the 2014 Plan, the 2020 Plan and the 2022 Inducement Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number of ​ Exercise ​ Contractual ​ Aggregate ​ ​ Shares ​ Price ​ Term ​ Intrinsic Value ​ ​ ​ ​ ​ ​ (in years) ​ (in thousands) Outstanding as of December 31, 2022 8,384,858 $ 8.59 8.30 $ 262 Granted ​ 2,361,118 ​ ​ 5.24 ​ — ​ ​ — Exercised(1) ​ (705,347) ​ ​ 3.85 ​ — ​ ​ — Forfeited ​ (1,064,318) ​ ​ 6.97 ​ — ​ ​ — Outstanding as of September 30, 2023 ​ 8,976,311 ​ $ 8.28 ​ 7.95 ​ $ 53,940 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options vested and exercisable as of September 30, 2023 ​ 4,343,726 ​ $ 9.91 ​ 7.34 ​ $ 23,679 Options expected to vest as of September 30, 2023 ​ 4,632,585 ​ $ 6.75 ​ 8.52 ​ $ 30,106 ​ (1) Exercised amount includes vesting of early-exercised options and shares returned for taxes withheld for exercise and net transactions. Early Exercise of Stock Options The terms of the 2014 Plan permit certain option holders to exercise options before their options are vested, subject to certain limitations. The early exercised options are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser’s employment, at the price paid by the purchaser. Such shares are not deemed to be outstanding for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. A liability is recognized related to the cash proceeds of the unvested options and is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. All early exercised options are vested as of September 30, 2023. ​ Restricted Stock Awards The following table summarizes the restricted stock activity under the 2014 Plan during the nine months ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares ​ Grant Date Fair Value Unvested restricted stock as of December 31, 2022 ​ 295,911 $ 2.40 Granted ​ ​ — ​ ​ — Vested ​ ​ (147,955) ​ ​ 2.40 Forfeited ​ ​ — ​ ​ — Unvested restricted stock as of September 30, 2023 ​ 147,956 ​ $ 2.40 ​ Performance-Based Restricted Stock Unit Awards In November 2022, the Company granted to certain employees 710,000 shares of performance-based restricted stock unit awards (the “PSUs”) under the 2020 Plan as consideration for services subject to performance conditions with a fair value based on the closing price of the underlying common stock on the date of grant. Pursuant to the terms of the PSUs, 65% of each PSU vests upon certification by the Compensation Committee of the Company of achieving a pre-determined performance goal by June 30, 2024, and 35% of each PSU vests upon certification by the Compensation Committee of the Company of achieving a pre-determined performance goal by June 30, 2024. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is met. As of September 30, 2023, the performance goals were not yet met, and therefore, the Company recorded zero stock-based compensation expense related to the PSUs for the three and nine months ended September 30, 2023. 2020 Employee Stock Purchase Plan In 2020, the Board and the Company’s stockholders approved and adopted the ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of the common stock purchased under the ESPP is equal to the lesser of (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. Each offering period is not to exceed 27 months and will include one or more purchase periods (each a “Purchase Period”) as approved by the Board in the offering. A total of 430,416 shares of common stock were initially reserved for issuance pursuant to the ESPP. Subsequently, the number of shares of the Company’s common stock reserved for issuance under the ESPP automatically increases on January 1 of each year for a period of up to ten years, commencing on January 1, 2021 and continuing through January 1, 2030, in amount equal to the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 860,832 shares of common stock, or (iii) a lesser number of shares determined by the Company’s Board of Directors no later than December 31 of the preceding calendar year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock-based compensation. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock offered under the ESPP. Stock-based compensation expense related to the ESPP was $0.1 million and $0.3 million for the three and nine months ended September 30, 2023, respectively. Stock-Based Compensation Expense Stock-based compensation expense related to awards granted under the 2014 Plan, the 2020 Plan, the ESPP and the 2022 Inducement Plan was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Research and development $ 2,801 $ 2,812 $ 8,858 $ 9,088 General and administrative 1,304 ​ ​ 1,463 4,047 ​ ​ 4,880 Total $ 4,105 ​ $ 4,275 $ 12,905 ​ $ 13,968 ​

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share
Net Loss Per Share	8. Net Loss Per Share Net Loss Per Share Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2023 2022 2023 2022 Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (21,502) ​ $ (22,720) ​ $ (69,883) ​ $ (78,608) Denominator: ​ ​ ​ ​ Weighted average shares used to compute net loss per share, basic and diluted ​ 44,977,161 ​ 40,036,201 ​ 41,999,978 ​ 39,930,418 Net loss per share, basic and diluted ​ $ (0.48) ​ $ (0.57) ​ $ (1.66) ​ $ (1.97) ​ The potentially dilutive shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ 2023 ​ ​ 2022 Unvested restricted stock awards outstanding ​ 147,956 ​ 345,230 Unvested performance-based restricted stock unit awards outstanding ​ ​ 665,000 ​ ​ — Options to purchase common stock ​ 8,976,311 ​ 8,329,948 Employee stock purchase plan contingently issuable ​ ​ 65,669 ​ ​ 182,139 ​ ​ ​ 9,854,936 ​ 8,857,317 ​

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	9. Leases The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2026. On June 1, 2013, the Company entered into a management services agreement with MandalMed, Inc. (the “MandalMed Services Agreement”) to have access to and use a portion of approximately 5,762 square feet of space for the use of laboratory benches, lab equipment, office space, and administrative and facilities services. The Company subsequently entered into six amendments to extend the agreement term to November 2023. As part of the sixth amendment, the Company gained access to use additional space of approximately 2,130 square feet for a three year period commencing on December 1, 2020 and ending on November 30, 2023. According to the terms of the MandalMed Services Agreement, the Company paid a security deposit of less than $0.1 million and is required to pay monthly rent and common area charges. On August 27, 2020, the Company entered into a lease agreement with 512 2nd Street LLC to lease approximately 3,500 square feet of office space in San Francisco, California (the “Office Space Lease Agreement”). The Office Space Lease Agreement was for a period of two years commencing on September 1, 2020 and ending August 31, 2022. In April 2022, the Company extended the Office Space Lease Agreement up to August 31, 2023 and had one year renewal option to extend the term up to August 31, 2024 On December 15, 2020, the Company entered into a lease agreement with Tennieh LLC to lease approximately 9,800 square feet of office space in San Francisco, California (the “Laboratory Lease Agreement”). The Laboratory Lease Agreement is for a period of five years commencing approximately February 1, 2021 and ending January 31, 2026. According to the terms of the Laboratory Lease Agreement, the Company paid a $0.4 million security deposit and is required to pay monthly rent and common area charges. On August 17, 2023, the Company entered into a sublease agreement with Dropbox, Inc. to sublease approximately 6,713 square feet of office space in San Francisco, California (the “Dropbox Sublease Agreement”). The Dropbox Sublease Agreement is for a period of two years commencing on September 5, 2023 and ending December 31, 2025. According to the terms of the Dropbox Sublease Agreement, the Company paid a $0.1 million security deposit and is required to pay monthly rent and common area charges. The sublease was accounted for under Topic 842 and the Company recorded ROU asset and lease liability of $0.2 million and $0.2 million, respectively, in the accompanying condensed consolidated financial statements. On August 23, 2023, the Company entered into a lease agreement with The Cambridge Redevelopment Authority to lease approximately 4,020 square feet of office space in Cambridge, Massachusetts (the “Cambridge Lease Agreement”). The Cambridge Lease Agreement is for a period of three years commencing on September 15, 2023 and ending September 14, 2026. According to the terms of the Cambridge Lease Agreement, the Company paid a less than $0.1 million security deposit and is required to pay monthly rent and common area charges. The lease was accounted for under Topic 842 and the Company recorded ROU asset and lease liability of $0.7 million and $0.7 million, respectively, in the accompanying condensed consolidated financial statements. The following table summarizes total lease expense during the three and nine months ended September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ ​ 2023 ​ ​ 2023 Straight-line operating lease expense ​ $ 320 $ 973 Short-term lease expense ​ 58 164 Variable lease expense ​ 42 62 Total operating lease expense ​ $ 420 $ 1,199 ​ The following table summarizes supplemental cash flow information during the three and nine months ended September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ ​ 2023 ​ ​ 2023 Cash paid for amounts included measurement of lease liabilities: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 315 ​ $ 968 Supplemental noncash information on lease liabilities arising from obtaining right-use-assets ​ $ 896 ​ $ 896 ​ The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of September 30, 2023 (in thousands): ​ ​ ​ ​ Years Ending December 31, ​ ​ ​ 2023 (from October 2023) $ 262 2024 1,162 2025 1,245 2026 ​ ​ 263 Total future minimum lease payments ​ 2,932 Less: Interest ​ ​ (309) Total lease liabilities at present value ​ ​ 2,623 Lease liabilities, current ​ ​ 924 Lease liabilities, non-current ​ $ 1,699 ​ The following table summarizes lease term and discount rate as of September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ 2023 Weighted-average remaining lease term (years) ​ 2.47 Weighted-average discount rate ​ 9.00% ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies.
Commitments and Contingencies	10. Commitments and Contingencies Loan Agreement On September 5, 2023, the Company entered into the Loan Agreement by and between the Company and the Bank. The Loan Agreement provides for a four-year senior secured credit facility in an aggregate principal amount of up to $50.0 million (the “Credit Facility”), of which $25.0 million became available upon the closing of the Private Placement, and the remaining $25.0 million may be made available upon approval of the Bank in its discretion. The Credit Facility will mature on August 1, 2027 (the “Maturity Date”). As of September 30, 2023, the Company had not drawn down from the Credit Facility. The obligations under the Loan Agreement are secured by substantially all of the assets of the Company, subject to limited exceptions. During the term of the Credit Facility, interest will accrue on any outstanding balance due under the Credit Facility at a floating rate per annum equal to the higher of (i) 8.0% and (ii) the prime rate. During an event of default, any outstanding amount under the Credit Facility will bear interest at a rate of 3.0% in excess of the otherwise applicable rate of interest. The Company will pay certain fees with respect to the Credit Facility, including a prepayment fee on any amount advanced under the Credit Facility to the extent paid prior to the Maturity Date, a final payment fee on the amount advanced under the Credit Facility, and an unused commitment fee of 1.5% on the portion of Credit Facility that remains undrawn as of June 30, 2024, as well as certain other fees and expenses of the Bank. The Loan Agreement contains customary events of default, including, but not limited to, nonpayment of principal, interest, fees or other amounts; material inaccuracy of a representation or warranty; failure to perform or observe covenants; cross-defaults with certain other indebtedness; bankruptcy and insolvency events; material monetary judgment defaults; material adverse change occurs; delisting; and a material impairment in the Bank’s security interest. Upon the occurrence of an event of default (subject, in certain cases, to notice and grace periods), obligations under the Loan Agreement may be accelerated. The Loan Agreement also contains a number of customary representations, warranties and covenants that, among other things, limit the ability of the Company to (subject to certain qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments in respect of its capital stock; amend certain material documents; redeem or repurchase certain debt; make payments on subordinated debt; and engage in certain transactions with affiliates. Clinical Collaboration and Supply Agreement On July 22, 2020, the Company entered into a non-exclusive clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”). On January 13, 2022, the Company entered into the amended and restated clinical collaboration and supply agreement with Novartis, and on October 9, 2023, the Company and Novartis entered into the amendment no. 1 (the “Novartis Amendment”) to amended and restated clinical collaboration and supply agreement (as amended, the “Novartis Agreement”). The collaboration is focused on the evaluation of the safety, tolerability and efficacy of palazestrant in combination with Novartis’ proprietary CDK4/6 inhibitor Kisqali® (ribociclib) and/or Novartis’ proprietary phosphatidylinositol 3-kinase (“PI3K a The Novartis Amendment, among other things, expanded our clinical collaboration with , increasing the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients. . The Company is responsible for manufacturing, packaging and labeling palazestrant, and for packaging and labeling all drugs used in the clinical trials for the combined therapies (other than the Novartis Study Drugs). Novartis is responsible for manufacturing and delivering to the Company the Novartis Study Drugs in such quantities as reasonably needed for the clinical trials for the combined therapies. In accordance with an agreed budget, subject to certain thresholds, Novartis will reimburse the Company for a majority of the direct outside costs that the Company incurs related to conducting the activities under the agreed development plan in conducting the clinical trials for the combined therapies. The Novartis Agreement will terminate upon completion of all activities outlined in the development plan and the relevant protocols. Either party may terminate the Novartis Agreement for the uncured material breach or insolvency of the other party, if it reasonably deems it necessary in order to protect the safety, health or welfare of subjects enrolled in the clinical trials for the combined therapies due to the existence of a material safety issue, or in certain circumstances for an unresolved clinical hold with respect to either the Novartis Study Drugs or palazestrant. In addition, Novartis may terminate the Novartis Agreement if certain disputes between the parties are not resolved after following the applicable dispute resolution procedures, and the Company may terminate the Novartis Agreement in the event the Company terminates all clinical trials of the combined therapies other than due to a material safety issue or upon a clinical hold. Costs associated with research activities performed under the agreement are included in research and development expenses in the accompanying condensed consolidated financial statements, with any reimbursable costs from Novartis reflected as a reduction of such expenses. For the three and nine months ended September 30, 2023, costs reimbursable from Novartis were $0.6 million and $2.0 million, respectively. As of September 30, 2023, the Company had incurred the full agreed-upon reimbursement amount. The receivable due from Novartis was $2.5 million, which is recorded under prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Clinical Trial Agreement In November 2020, the Company entered into a non-exclusive clinical trial agreement with Pfizer Inc. (“Pfizer”) (the “Pfizer Agreement”), to evaluate the safety and tolerability of palazestrant in combination with Pfizer’s proprietary CDK4/6 inhibitor IBRANCE® (palbociclib) in patients with recurrent, locally advanced or metastatic ER+, HER2 breast cancer in a clinical trial. Under the terms of the non-exclusive agreement, the Company will be responsible for conducting the clinical trial for the combined therapies and Pfizer is responsible for supplying IBRANCE® to the Company at no cost to the Company. As part of the collaboration, the parties granted to each other a non-exclusive, royalty-free license under certain of the parties’ respective patent rights in the combination of IBRANCE® and palazestrant to use the parties’ respective study drugs in research and development, solely to the extent reasonably needed for the other party’s activities in the collaboration. All inventions and data developed in the performance of the clinical trials for the combined therapies (other than those specific to each component study drug), will be jointly owned by the parties. The Company is responsible for manufacturing, packaging and labeling palazestrant, and for packaging and labeling all drugs used in the clinical trials for the combined therapies (other than IBRANCE®). Pfizer is responsible for manufacturing and delivering to us IBRANCE® in such quantities as reasonably needed for the clinical trials for the combined therapies. The Pfizer Agreement will terminate upon completion of all activities outlined in the study plan and the relevant protocols. Either party may terminate the Pfizer Agreement for the uncured material breach or insolvency of the other party, if it reasonably deems it necessary in order to protect the safety, health or welfare of subjects enrolled in the clinical trials for the combined therapies due to the existence of a material safety issue, or in certain circumstances for an unresolved clinical hold with respect to either the IBRANCE® or palazestrant. In addition, either party may terminate the Pfizer Agreement if certain disputes between the parties are not resolved after following the applicable dispute resolution procedures or if either party determines to discontinue clinical development for medical, scientific, legal or other reasons. The Pfizer Agreement does not grant any right of first negotiation to participate in future clinical trials, and each of the parties retains all rights and ability to evaluate their respective compounds. Costs incurred in connection to the Pfizer Agreement are included in the research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023, and 2022. License Agreement In June 2022, the Company entered into an exclusive global license agreement with Aurigene Discovery Technologies Limited (“Aurigene”) to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target (“the Aurigene Agreement”). Under the terms of the Aurigene Agreement, Aurigene will provide to the Company an exclusive license to its portfolio of novel small molecule inhibitors of the target. Financial terms of the Aurigene Agreement include a $8.0 million upfront payment for rights to a pre-existing Aurigene program and potential future milestone payments of up to $60.0 million in clinical development and regulatory milestones, and up to $370.0 million in commercial milestones. Aurigene is also eligible to receive mid-single digits to the low double digits royalties on product sales, if any. During the research term, the Company will contribute funding to Aurigene to facilitate Aurigene’s ongoing discovery efforts. The Company and Aurigene will jointly direct further preclinical work and, if successful, the Company will lead clinical development as well as regulatory and commercial activities. The Company and Aurigene jointly own collaboration compounds and rights to any inventions made during the research term. The term of the Aurigene Agreement will continue until the expiration of the last-to-expire of all payment obligations with respect to all licensed products thereunder, unless terminated earlier in accordance with the terms of the Aurigene Agreement. The Aurigene Agreement may be terminated (a) by the Company for convenience, in its sole discretion, upon prior written notice to Aurigene, (b) by either the Company or Aurigene in connection with the other party’s uncured material breach or (c) by either the Company or Aurigene in connection with the insolvency of the other party. The $8.0 million upfront payment was incurred in June 2022 and recorded as research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs incurred and milestones payments due to Aurigene prior to regulatory approval are recognized as research and development expenses in the period incurred. Payments due to Aurigene upon or subsequent to regulatory approval will be accrued as a provision to cost of sales in the period when achievement of respective milestone target is probable. As of September 30, 2023, it was determined that it is not probable to achieve any of the milestone targets, and therefore, the Company recorded zero expense related to the milestone for the three and nine months ended September 30, 2023. Management Services Agreements The Company conducts research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants, CMOs, and CROs. The Company has contractual arrangements in the normal course of business with these parties, however, the contracts with these parties are cancelable generally on reasonable notice within one year and the Company’s obligations under these contracts are primarily based on services performed through termination dates plus certain cancelation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties. As of September 30, 2023, the Company did not have material contractual commitments with respect to these arrangements. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of September 30, 2023, and December 31, 2022, the Company had not incurred any material costs as a result of such indemnifications.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting, and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements include the accounts of Olema Pharmaceuticals, Inc. and its wholly-owned subsidiary, Olema Oncology Australia Pty Ltd. All intercompany balances and transactions have been eliminated upon consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The interim condensed consolidated balance sheet as of September 30, 2023, and the statements of operations and comprehensive loss, and stockholders’ equity for the three and nine months ended September 30, 2023 and 2022, and the statements of cash flows for the nine months ended September 30, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial statements included in this report. The financial data and the other information disclosed in these notes to the condensed consolidated financial statements related to the three- and nine-month periods are also unaudited. The results of operations presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results to be expected for the year ending December 31, 2023, or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K as filed with the SEC on March 9, 2023 (the “Annual Report”).
Use of Estimates	Use of Estimates The accompanying condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Significant areas that require management’s estimates include accruals of research and development expenses, including accrual of research contract costs, stock-based compensation assumptions, including the fair value of common stock. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or fewer at the date of purchase. Cash deposits are all in reputable financial institutions in the United States as of September 30, 2023, and December 31, 2022. Cash and cash equivalents consisted of cash on deposit with U.S. banks, including the Company’s bank account for its Australia subsidiary, denominated in U.S. dollars and Australian dollars and investments in interest bearing money market funds.
Marketable Securities	Marketable Securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each balance sheet date. Unrealized gains and losses are excluded from net loss and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest earned on marketable securities is included in interest income. The Company periodically assesses its available-for-sale marketable securities for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through other expense. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through other expense, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive loss. The Company has not recorded any impairments for its marketable securities.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company invests in a variety of financial instruments and, by its policy, limits these financial instruments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks and corporations, subject to certain concentration limits. The Company’s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit with individual banking institutions may at times exceed the limits insured by the Federal Deposit Insurance Corporation (“FDIC”); however, the Company has not experienced any losses on such deposits. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships, dependence on key individuals or sole-source suppliers, and geopolitical and macroeconomic factors. The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company were denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.
Leases	Leases The Company adopted Accounting Standard Update (“ASU”) 2016-12, Leases At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease, the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or finance lease; and (iv) recognizes lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses the incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. Most leases include options to renew and, or terminate the lease, which can impact the lease term. The exercise of these options is at the Company’s discretion. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. For any lease modification, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate that reflects the modified lease term, and adjusts the related ROU asset under the lease modification guidance under Topic 842. The Company has operating leases for its research and development and office facilities. Fixed lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our condensed consolidated statements of operations and comprehensive loss. The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less. Additional information and disclosures required by Topic 842 are contained in Note 11 “Lease” in the Annual Report.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates. These costs are recorded within research and development expenses in the condensed consolidated statements of operations and include personnel expenses, stock-based compensation expenses, allocated general and administrative expenses, and external costs including fees paid to consultants and contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), in connection with nonclinical studies and clinical trials, and other related clinical trial fees, such as for investigator fees, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses and other current assets. Such amounts are recognized as an expense as the goods are delivered or the related services are performed. Costs incurred in obtaining technology licenses that do not meet the definition of a business are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future uses. Reimbursements of certain costs associated with research activities performed under the agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) are recorded as a reduction of research and development expenses and as a receivable due from Novartis, which is recorded under prepaid expenses and other current assets in the accompanying condensed consolidated financial statements, as described in Note 10, Commitments and Contingencies – Clinical Collaboration and Supply Agreement.
Research Contract Costs and Accruals	Research Contract Costs and Accruals The Company has from time to time entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the projects, studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share is computed by dividing the net loss per common share by the weighted average number of common shares outstanding for the period without consideration of common stock equivalents. Diluted net loss per common share is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities, and by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, including unvested early exercised options, unvested restricted stock awards, unvested performance-based restricted stock unit awards and contingently issuable common stock related to the 2020 Employee Stock Purchase Plan (the “ESPP”) are considered potential dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were no new accounting pronouncements that were relevant to the Company as of and for the nine months ended September 30, 2023. ​

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement
Schedule of financial assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 (in thousands) Level 1 ​ Level 2 ​ Level 3 ​ Total Financial Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash ​ $ 2,712 ​ $ — ​ $ — ​ $ 2,712 Money market funds ​ ​ 115,029 ​ ​ — ​ ​ — ​ ​ 115,029 Commercial paper ​ — ​ ​ 87,639 ​ ​ — ​ ​ 87,639 Corporate bonds ​ ​ — ​ ​ 3,626 ​ ​ — ​ ​ 3,626 U.S. government treasury bills ​ ​ 37,395 ​ ​ — ​ ​ — ​ ​ 37,395 Government-sponsored enterprise securities ​ — ​ ​ 30,834 ​ ​ — ​ ​ 30,834 Total ​ $ 155,136 ​ $ 122,099 ​ $ — ​ $ 277,235
Schedule of financial assets reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Estimated (in thousands) Cost ​ Gains ​ Losses ​ Fair Value Financial Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 117,741 ​ $ — ​ $ — ​ $ 117,741 Short-term marketable securities (<12 months to maturity) ​ ​ 156,108 ​ ​ 9 ​ ​ (249) ​ ​ 155,868 Long-term marketable securities (>12 months to maturity) ​ ​ 3,627 ​ ​ — ​ ​ (1) ​ ​ 3,626 Total ​ $ 277,476 ​ $ 9 ​ $ (250) ​ $ 277,235

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2023
Property and Equipment, net
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Lab equipment $ 1,695 $ 2,002 Computer equipment ​ ​ 59 ​ ​ 59 Property and equipment, gross ​ ​ 1,754 ​ ​ 2,061 Less: Accumulated depreciation (698) ​ ​ (581) Property and equipment, net $ 1,056 ​ $ 1,480 ​

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses and Other Current Assets
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Reimbursable research and development costs from a collaboration partner ​ $ 2,467 ​ $ 1,387 Prepaid clinical development costs ​ 1,003 ​ 506 Prepaid insurance ​ ​ 384 ​ ​ 1,738 Interest receivable ​ ​ 419 ​ ​ 319 Research and development tax incentive credit receivable ​ ​ 321 ​ ​ — Prepaid subscriptions and licenses ​ ​ 239 ​ ​ 399 Other 274 ​ ​ 129 Total $ 5,107 ​ $ 4,478 ​

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Accrued and Other Current Liabilities
Schedule of accrued and other current liabilities	Accrued and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2023 ​ 2022 Accrued research and development related costs ​ $ 8,370 ​ $ 9,105 Accrued employee bonuses ​ ​ 2,849 ​ ​ 4,518 Accrued professional fees ​ ​ 1,143 ​ ​ 1,091 Accrued payroll related costs ​ ​ 416 ​ ​ 296 Accrued taxes ​ ​ 57 ​ ​ 68 Early exercise of unvested stock options ​ ​ — ​ ​ 82 Total $ 12,835 ​ $ 15,160

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation
Schedule of fair value assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2023 ​ 2022 Risk-free interest rate ​ 3.56% ​ 1.89% Expected term (in years) ​ ​ 6.03 ​ ​ 6.03 Expected volatility ​ ​ 86.71% ​ ​ 79.55% Expected dividend yield — ​ ​ —
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number of ​ Exercise ​ Contractual ​ Aggregate ​ ​ Shares ​ Price ​ Term ​ Intrinsic Value ​ ​ ​ ​ ​ ​ (in years) ​ (in thousands) Outstanding as of December 31, 2022 8,384,858 $ 8.59 8.30 $ 262 Granted ​ 2,361,118 ​ ​ 5.24 ​ — ​ ​ — Exercised(1) ​ (705,347) ​ ​ 3.85 ​ — ​ ​ — Forfeited ​ (1,064,318) ​ ​ 6.97 ​ — ​ ​ — Outstanding as of September 30, 2023 ​ 8,976,311 ​ $ 8.28 ​ 7.95 ​ $ 53,940 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options vested and exercisable as of September 30, 2023 ​ 4,343,726 ​ $ 9.91 ​ 7.34 ​ $ 23,679 Options expected to vest as of September 30, 2023 ​ 4,632,585 ​ $ 6.75 ​ 8.52 ​ $ 30,106 ​ (1) Exercised amount includes vesting of early-exercised options and shares returned for taxes withheld for exercise and net transactions.
Summary of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares ​ Grant Date Fair Value Unvested restricted stock as of December 31, 2022 ​ 295,911 $ 2.40 Granted ​ ​ — ​ ​ — Vested ​ ​ (147,955) ​ ​ 2.40 Forfeited ​ ​ — ​ ​ — Unvested restricted stock as of September 30, 2023 ​ 147,956 ​ $ 2.40
Schedule of stock-based compensation expense	Stock-based compensation expense related to awards granted under the 2014 Plan, the 2020 Plan, the ESPP and the 2022 Inducement Plan was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Research and development $ 2,801 $ 2,812 $ 8,858 $ 9,088 General and administrative 1,304 ​ ​ 1,463 4,047 ​ ​ 4,880 Total $ 4,105 ​ $ 4,275 $ 12,905 ​ $ 13,968 ​

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share
Schedule of basic and diluted net loss per share	Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2023 2022 2023 2022 Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (21,502) ​ $ (22,720) ​ $ (69,883) ​ $ (78,608) Denominator: ​ ​ ​ ​ Weighted average shares used to compute net loss per share, basic and diluted ​ 44,977,161 ​ 40,036,201 ​ 41,999,978 ​ 39,930,418 Net loss per share, basic and diluted ​ $ (0.48) ​ $ (0.57) ​ $ (1.66) ​ $ (1.97)
Schedule of anti-dilutive securities excluded from computation of diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ 2023 ​ ​ 2022 Unvested restricted stock awards outstanding ​ 147,956 ​ 345,230 Unvested performance-based restricted stock unit awards outstanding ​ ​ 665,000 ​ ​ — Options to purchase common stock ​ 8,976,311 ​ 8,329,948 Employee stock purchase plan contingently issuable ​ ​ 65,669 ​ ​ 182,139 ​ ​ ​ 9,854,936 ​ 8,857,317 ​

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Summary of total lease expense	The following table summarizes total lease expense during the three and nine months ended September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ ​ 2023 ​ ​ 2023 Straight-line operating lease expense ​ $ 320 $ 973 Short-term lease expense ​ 58 164 Variable lease expense ​ 42 62 Total operating lease expense ​ $ 420 $ 1,199
Summary of supplemental cash flow information	The following table summarizes supplemental cash flow information during the three and nine months ended September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ ​ 2023 ​ ​ 2023 Cash paid for amounts included measurement of lease liabilities: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 315 ​ $ 968 Supplemental noncash information on lease liabilities arising from obtaining right-use-assets ​ $ 896 ​ $ 896
Summary of future minimum lease payments	The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of September 30, 2023 (in thousands): ​ ​ ​ ​ Years Ending December 31, ​ ​ ​ 2023 (from October 2023) $ 262 2024 1,162 2025 1,245 2026 ​ ​ 263 Total future minimum lease payments ​ 2,932 Less: Interest ​ ​ (309) Total lease liabilities at present value ​ ​ 2,623 Lease liabilities, current ​ ​ 924 Lease liabilities, non-current ​ $ 1,699
Summary of lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ 2023 Weighted-average remaining lease term (years) ​ 2.47 Weighted-average discount rate ​ 9.00% ​

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Details) $ / shares in Units, $ in Thousands		9 Months Ended
	Sep. 05, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) segment
Number of operating segments | segment		1
Number of reportable segments | segment		1
Cash, cash equivalents and marketable securities		$ 276,900
Offering expenses of private placement		240
Net proceeds of private placement		129,760
Senior Secured Loan Facility
Amount available for draw down, Lenders discretion	$ 25,000	$ 25,000
Private Placement
Shares issued in private placement | shares	13,211,381
Share Price | $ / shares	$ 9.84
Gross proceeds of private placement	$ 130,000
Offering expenses of private placement	200
Net proceeds of private placement	$ 129,800

Fair Value Measurement (Details

Fair Value Measurement (Details) - Recurring $ in Thousands	Sep. 30, 2023 USD ($)
Assets
Cash	$ 2,712
Total	277,235
Level 1
Assets
Cash	2,712
Total	155,136
Level 2
Assets
Total	122,099
Money market funds
Assets
Cash	115,029
Money market funds | Level 1
Assets
Cash	115,029
Commercial paper
Assets
Marketable securities	87,639
Commercial paper | Level 2
Assets
Marketable securities	87,639
Corporate bonds
Assets
Marketable securities	3,626
Corporate bonds | Level 2
Assets
Marketable securities	3,626
U.S. government treasury bills
Assets
Marketable securities	37,395
U.S. government treasury bills | Level 1
Assets
Marketable securities	37,395
Government-sponsored enterprise securities
Assets
Marketable securities	30,834
Government-sponsored enterprise securities | Level 2
Assets
Marketable securities	$ 30,834

Fair Value Measurement - Market

Fair Value Measurement - Marketable Securities (Details) $ in Thousands	Sep. 30, 2023 USD ($) security
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	$ 277,476
Gross Unrealized Gains	9
Gross Unrealized Losses	(250)
Estimated Fair Value	277,235
Allowance for losses on available-for-sale debt securities	$ 0
Marketable securities in an unrealized loss position for more than 12 months | security	7
Security in continuous unrealized loss position, more than 12 months, accumulated loss	$ 100
Security in continuous unrealized loss position, more than 12 months, fair value	19,400
Cash and cash equivalents
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	117,741
Estimated Fair Value	117,741
Short-term marketable securities
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	156,108
Gross Unrealized Gains	9
Gross Unrealized Losses	(249)
Estimated Fair Value	155,868
Long-term marketable securities
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	3,627
Gross Unrealized Losses	(1)
Estimated Fair Value	$ 3,626

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,754	$ 2,061
Less: Accumulated depreciation	(698)	(581)
Property and equipment, net	1,056	1,480
Lab equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,695	2,002
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 59	$ 59

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets
Reimbursable research and development costs from a collaboration partner	$ 2,467	$ 1,387
Prepaid clinical development costs	1,003	506
Prepaid insurance	384	1,738
Interest receivable	419	319
Research and development tax incentive credit receivable	321
Prepaid subscriptions and licenses	239	399
Other	274	129
Total	$ 5,107	$ 4,478

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accrued and Other Current Liabilities
Accrued research and development related costs	$ 8,370	$ 9,105
Accrued employee bonuses	2,849	4,518
Accrued professional fees	1,143	1,091
Accrued payroll related costs	416	296
Accrued taxes	57	68
Early exercise of unvested stock options		82
Total	$ 12,835	$ 15,160

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of common stock at fair market value to be exercised	100%
Expiration period (in years)	10 years
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New shares authorized		2,152,080
Period of increase in common stock reserved for issuance		10 years
Percentage of increase in common stock reserved for issuance		5%
2020 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		6,494,510
Shares available from prior equity incentive plan		4,342,430
2022 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	2,000,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Valuation (Details)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Stock-Based Compensation
Risk-free interest rate	3.56%	1.89%
Expected term (in years)	6 years 10 days	6 years 10 days
Expected volatility	86.71%	79.55%
Expected dividend yield	0%	0%

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Number of shares
Outstanding as at beginning of period (in shares) | shares	8,384,858
Granted (in shares) | shares	2,361,118
Exercised (in shares) | shares	(705,347)
Forfeited (in shares) | shares	(1,064,318)
Outstanding as at end of period (in shares) | shares	8,976,311	8,384,858
Options vested and exercisable as at end of period (in shares) | shares	4,343,726
Options expected to vest as at end of period (in shares) | shares	4,632,585
Weighted Average Exercise Price
Outstanding as at beginning of period (in dollars per share) | $ / shares	$ 8.59
Granted (in dollars per share) | $ / shares	5.24
Exercised (in dollars per share) | $ / shares	3.85
Forfeited (in dollars per share) | $ / shares	6.97
Outstanding at end of period (in dollars per share) | $ / shares	8.28	$ 8.59
Options vested and exercisable as at end of period (in dollars per share) | $ / shares	9.91
Options expected to vest as at end of period (in dollars per share) | $ / shares	$ 6.75
Weighted Average Remaining Contractual Life
Weighted average remaining contractual life of outstanding options (in years)	7 years 11 months 12 days	8 years 3 months 18 days
Weighted average remaining contractual life of vested and exercisable options (in years)	7 years 4 months 2 days
Weighted average remaining contractual life of expected to vest options (in years)	8 years 6 months 7 days
Intrinsic value of outstanding options | $	$ 53,940	$ 262
Intrinsic value of vested and exercisable options | $	23,679
Intrinsic value of expected to vest options | $	$ 30,106

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares
Unvested restricted stock as at beginning of period (in shares) | shares	295,911
Vested (in shares) | shares	(147,955)
Unvested restricted stock as at end of period (in shares) | shares	147,956
Grant Date Fair Value
Unvested restricted stock as at beginning of period (in dollars per share) | $ / shares	$ 2.40
Vested (in dollars per share) | $ / shares	2.40
Unvested restricted stock as at ending of period (in dollars per share) | $ / shares	$ 2.40

Stock Based Compensation - Perf

Stock Based Compensation - Performance-Based Restricted Stock Unit Awards (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 4,105,000	$ 4,275,000	$ 12,905,000	$ 13,968,000
Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	710,000
Stock-based compensation expense		$ 0		$ 0
Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee | Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Percentage	65%
Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee | Share-Based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Percentage	35%

Stock-Based Compensation - 2020

Stock-Based Compensation - 2020 Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2020
Stock-Based Compensation
Percent of common stock at fair market value to be exercised					100%
Stock-based compensation expense	$ 4,105	$ 4,275	$ 12,905	$ 13,968
ESPP 2020 Plan
Stock-Based Compensation
Percentage of eligible earnings withheld						15%
Percent of common stock at fair market value to be exercised						85%
Common stock reserved for issuance						430,416
Stock-based compensation expense	$ 100		$ 300
Period of increase in common stock reserved for issuance						10 years
Common stock outstanding percentage						1%
Shares of common stock						860,832
Maximum | ESPP 2020 Plan
Stock-Based Compensation
Offering period						27 months

Stock-Based Compensation - St_3

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-based compensation expense
Total stock-based compensation expense	$ 4,105	$ 4,275	$ 12,905	$ 13,968
Research and development
Stock-based compensation expense
Total stock-based compensation expense	2,801	2,812	8,858	9,088
General and administrative
Stock-based compensation expense
Total stock-based compensation expense	$ 1,304	$ 1,463	$ 4,047	$ 4,880

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss	$ (21,502)	$ (22,720)	$ (69,883)	$ (78,608)
Denominator:
Weighted average shares used to compute net loss per share, basic (in shares)	44,977,161	40,036,201	41,999,978	39,930,418
Weighted average shares used to compute net loss per share, diluted (in shares)	44,977,161	40,036,201	41,999,978	39,930,418
Net loss per share, basic (in dollars per share)	$ (0.48)	$ (0.57)	$ (1.66)	$ (1.97)
Net loss per share, diluted (in dollars per share)	$ (0.48)	$ (0.57)	$ (1.66)	$ (1.97)

Net Loss Per Share - Anti-dilut

Net Loss Per Share - Anti-dilutive Effect (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	9,854,936	8,857,317
Unvested restricted stock awards outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	147,956	345,230
Unvested performance-based restricted stock unit awards outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	665,000
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	8,976,311	8,329,948
Employee stock purchase plan contingently issuable
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	65,669	182,139

Leases (Details)

Leases (Details) $ in Thousands	1 Months Ended
	Apr. 30, 2022	Sep. 30, 2023 USD ($)	Aug. 23, 2023 USD ($) ft²	Aug. 17, 2023 USD ($) ft²	Dec. 31, 2022 USD ($)	Dec. 15, 2020 USD ($) ft²	Dec. 01, 2020 USD ($) ft²	Aug. 27, 2020 USD ($) ft²	Jun. 01, 2013 ft² item
Lease
Operating lease right-of-use assets		$ 2,558			$ 2,495
Lease liabilities		$ 2,623
MandalMed Services Agreement Area
Lease
Number of lease amendments | item									6
Area of property | ft²									5,762
Mandalmed Services Agreement Additional Area
Lease
Area of property | ft²							2,130
Term of contract							3 years
Security deposit							$ 100
Office Space
Lease
Area of property | ft²								3,500
Term of contract								2 years
Renewal term	1 year
Renewal option	true
Security deposit								$ 100
Laboratory Lease Agreement
Lease
Area of property | ft²						9,800
Term of contract						5 years
Security deposit						$ 400
Dropbox Sublease Agreement
Lease
Area of property | ft²				6,713
Term of contract				2 years
Security deposit				$ 100
Operating lease right-of-use assets				200
Lease liabilities				$ 200
Cambridge Lease Agreement
Lease
Area of property | ft²			4,020
Term of contract			3 years
Operating lease right-of-use assets			$ 700
Lease liabilities			700
Cambridge Lease Agreement | Minimum
Lease
Security deposit			$ 100

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Lease expense
Straight-line operating lease expense	$ 320	$ 973
Short-term lease expense	58	164
Variable lease expense	42	62
Total operating lease expense	$ 420	$ 1,199

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Leases
Operating cash flows from operating leases	$ 315	$ 968
Supplemental noncash information on lease liabilities arising from obtaining right-use-assets	$ 896	$ 896

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Future minimum lease payments
2023 (from October 2023)	$ 262
2024	1,162
2025	1,245
2026	263
Total future minimum lease payments	2,932
Less: Interest	(309)
Total lease liabilities at present value	2,623
Lease liabilities, current	924	$ 1,015
Lease liabilities, non-current	$ 1,699	$ 1,550

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Sep. 30, 2023
Leases
Weighted-average remaining lease term (years)	2 years 5 months 19 days
Weighted-average discount rate	9%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 05, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) item	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) item	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Reimbursable research and development costs from a collaboration partner			$ 2,467		$ 2,467		$ 1,387
Research and development			19,453	$ 17,627	60,268	$ 60,690
Senior Secured Loan Facility
Loss Contingencies [Line Items]
Term of loan agreement	4 years
Aggregate principal amount	$ 50,000
Amount available for draw down, Private placement.	25,000
Amount available for draw down, Lenders discretion	$ 25,000		$ 25,000		$ 25,000
Interest rate	8%
Incremental interest rate at the event of default	3%
Unused commitment fee percentage	1.50%
Novartis Agreement
Loss Contingencies [Line Items]
Number of patients | item			60		60
Novartis Agreement | Bio Medical Research Inc
Loss Contingencies [Line Items]
Costs reimbursable from Novartis			$ 600		$ 2,000
Reimbursable research and development costs from a collaboration partner			2,500		2,500
Aurigene Agreement
Loss Contingencies [Line Items]
Milestone payments to be paid to collaborative partner		$ 60,000
Upfront payment, research and development.		8,000
Research and development			$ 0		$ 0
Aurigene Agreement | Commercial Milestone
Loss Contingencies [Line Items]
Milestone payments to be paid to collaborative partner		$ 370,000